

Author Query Form

WILEY

Journal: ANAE

Article: 15461

Dear Author,



During the copyediting of your manuscript the following queries arose.

Please refer to the query reference callout numbers in the page proofs and respond to each by marking the necessary comments using the PDF annotation tools.

Please remember illegible or unclear comments and corrections may delay publication.

Many thanks for your assistance.

AUTHOR: Please note that missing content in references have been updated where we have been able to match the missing elements without ambiguity against a standard citation database, to meet the reference style requirements of the journal. It is your responsibility to check and ensure that all listed references are complete and accurate.

Query reference	Query	Remarks
1	AUTHOR: Please confirm that given names (blue) and surnames/family names (vermilion) have been identified correctly.	
2	AUTHOR: Please verify that the linked ORCID identifier is correct.	

Science Letter

Prevalence, management and outcomes associated with anaemia in ICU survivors: a retrospective study

Survivors of critical illness experience poor health-related quality of life, especially during the first year following discharge from intensive care unit (ICU) [1]. Identification of modifiable risk-factors and enhancing recovery from critical illness is now a recognised clinical and research priority.

Recent observational studies have demonstrated that anaemia in this cohort is associated with increased mortality, poor physical recovery, increased dependency and high levels of fatigue in the post-ICU recovery period [2–4]. Intensive care unit survivors display the hallmarks of anaemia of inflammation, which may be treatable with interventions such as intravenous iron but there is no literature describing how clinicians caring for ICU survivors manage anaemia. The aims of this study were to determine the prevalence, characteristics and management of anaemia in a large cohort of ICU survivors before hospital discharge.

We undertook a retrospective cohort study of general ICU survivors in two large health regions in the UK (Oxford University Hospitals NHS Foundation Trust, 1 December 2014–31 May 2015; Royal Infirmary of Edinburgh, 1 January 2015–31 December 2015) aiming to benchmark how many patients had anaemia-specific treatment (excluding blood transfusion) initiated before hospital discharge.

Data on patient baseline characteristics, acute physiology and chronic health evaluation-2 scores, admission categories and ICU and hospital length of stay were extracted along with haemoglobin (Hb) at ICU admission, ICU discharge and hospital discharge. We reviewed discharge summaries and prescription charts of all survivors for any documentation regarding management of anaemia. We also conducted exploratory multivariable analyses to investigate the associations between anaemia at ICU discharge and clinical outcomes, and any factors associated with Hb at hospital discharge. Anaemia was categorised as Hb < 100 g.l⁻¹ based on research, in critically and non-critically ill patients, which has found associations between this threshold and persisting anaemia [5] together with poor outcomes [2].

Complete data were available for 1174 ICU patients who survived to hospital discharge. Baseline and clinical characteristics are displayed in Table 1. In total, 626 patients were discharged from ICU with Hb < 100 g.l⁻¹ (53.3%). Of these, 289 (46%) patients still had Hb < 100 g.l⁻¹

at hospital discharge compared with 149 (27.2%) of patients who were discharged from ICU with Hb > 100 g.l⁻¹. Fifty-two (4.4%) patients received oral iron before hospital discharge. One patient received intravenous iron and two received vitamin B12 and folate. There was no mention of anaemia treatment and/or follow-up in any of the other discharge letters reviewed.

Patients discharged from ICU with Hb < 100 g.l⁻¹ experienced a longer median (IQR [range]) post-ICU hospital length of stay when compared with those discharged with Hb > 100 g.l⁻¹ (8 (4–15 [1–153]) vs. 3 (7–13 [1–106]) days, $p = 0.0017$) (Table 1). Following adjustment for covariates, Hb < 100 g.l⁻¹ was associated with prolonged hospitalisation, defined as post-ICU length of stay > 7 days (relative risk (95%CI): 1.36 (1.10–1.68)). Factors associated with Hb at hospital discharge were acute physiology and chronic health evaluation-2 score, ICU discharge Hb and ICU length of stay (Table 2).

The key findings of this study were a high prevalence of anaemia at ICU discharge and subsequently hospital discharge; there is little active management of anaemia during this important time period; and Hb of < 100 g.l⁻¹ was associated with prolonged hospitalisation following ICU discharge. The latter finding may identify a group of patients who may benefit from closer follow-up.

The high prevalence of anaemia persisting at ICU and hospital discharge may, in part, be explained by increased adherence to restrictive transfusion thresholds recommended by guidelines [4]. However, our findings showed little change from over a decade ago [4, 5]. Although our data cannot establish causality, our findings support a causal pathway in which anaemia, as a driver of functional impairment, results in an increased requirement for hospitalisation following ICU discharge. Correcting anaemia may improve clinical outcomes, which have been shown in recent observational studies where a higher Hb at discharge was associated with improvements in functional activities, physical performance and lower mortality [6, 7].

Our study cohort was an unselected population from two large general ICUs with a case-mix typical of admissions to other ICUs and therefore our data are externally generalisable. Our study is subject to the usual limitations of


Dispatch: 14.3.21	CE: Stella	PE: Balakumar C.
No. of pages: 3	WILEY	15461
Journal Code	Manuscript No.	A N A E
		

Table 1 Clinical characteristics of hospital survivors stratified by anaemia severity at ICU discharge. Values are median (IQR [range]), mean (SD) and number (proportion)

Characteristic	All patients n = 1174	Hb < 100 g.l ⁻¹ n = 626	Hb ≥ 100 g.l ⁻¹ n = 548	p value
Age	58 (42–69 [17–114])	57 (41–68 [16–94])	58 (42–70 [18–114])	
Sex				
Male	692 (58.9)	360 (57.5)	332 (60.6)	
Female	482 (41.4)	266 (42.5)	216 (39.4)	
APACHE 2	15.4 (7.0)	15.7 (7.2)	15.0 (6.7)	
Admission category				
Emergency/urgent surgery	312 (26.6)	147 (23.5)	165 (30.1)	
Elective surgery	457 (38.9)	223 (35.6)	234 (42.7)	
Medical	405 (34.5)	256 (40.9)	149 (27.2)	
Haemoglobin, g.l ⁻¹				
ICU admission	120 (102–135 [63–172])	113 (97–131 [61–169])	124 (108–137 [66–174])	
ICU discharge	96 (91–116 [57–171])	91 (89–91 [57–99])	116 (104–126 [100–171])	
Hospital discharge	105 (93–119 [61–177])	101 (90–115 [61–177])	110 (98–125 [62–171])	
Proportion discharged from hospital with Hb < 100 g.l ⁻¹	438/1174 (37.3%)	289/626 (46.2%)	149/548 (27.2%)	< 0.0001
ICU length of stay, days	2 (1–5 [0–73])	3 (2–5 [0–54])	2 (1–4 [0–73])	
Post-ICU length of stay in hospital, days	7 (3–14 [1–153])	8 (4–15 [1–153])	3 (7–13 [1–106])	0.0017

APACHE, acute physiology and chronic health evaluation; Hb, haemoglobin.

Table 2 Multivariable analysis of factors associated with haemoglobin at hospital discharge

Variable	Regression coefficient (95%CI)	p value
APACHE 2 ^a	−0.14 (−0.25 to −0.04)	0.006
ICU discharge Hb, g.l ⁻¹	0.11 (0.07 to 0.16)	< 0.001
Sex (female)	−0.75 (−2.48 to 0.97)	0.393
ICU length of stay	−0.48 (−0.62 to −0.35)	< 0.001
Post-ICU length of stay	0.01 (−0.07 to 0.04)	0.626

APACHE, acute physiology and chronic health evaluation; Hb, haemoglobin.

^aAPACHE 2 score includes other important variables such as age, severe comorbidity and emergency admission.

observational studies such as unmeasured confounding. We did not collect data on factors that may influence recovery from anaemia such as red blood cell transfusion, inflammation and pre-existing comorbidities.

Early stage randomised controlled trials are currently ongoing to determine whether treating anaemia in the post-ICU period, with interventions such as iron [8] and red blood cell transfusion, improves clinical outcomes. Given the heterogeneous nature of the population of ICU survivors, there is also a need to further define the aetiology and trajectories of post-ICU anaemia in order to identify which patients may benefit the most from anaemia management.

Acknowledgements

AS is being supported by an NIHR Doctoral Research Fellowship. No external funding or competing interests declared.

Collaborators

Dr S. R. McKechnie, Oxford University Hospitals NHS Foundation Trust, Oxford, UK; Dr J. Dickerson, University of Oxford Medical School, Oxford, UK; Dr D. M. Griffith, University of Edinburgh, Edinburgh, UK; Professor T. S. Walsh, University of Edinburgh, Edinburgh, UK.

A. Shah 

S. J. Stanworth

Radcliffe Department of Medicine, University of Oxford, Oxford, UK
Email: akshay.shah@linacre.ox.ac.uk

A. Lee

Royal Berkshire Hospital NHS Foundation Trust, Reading, UK

L. Johnston

University of Edinburgh Medical School, Edinburgh, UK

A. B. Docherty

The Usher Institute, The University of Edinburgh, Edinburgh, UK

1 2

References

1. Gerth AMJ, Hatch RA, Young JD, Watkinson PJ. Changes in health-related quality of life after discharge from an intensive care unit: a systematic review. *Anaesthesia* 2019; **74**: 100–8.
2. Lasocki S, Chudeau N, Papet T, et al. Prevalence of iron deficiency on ICU discharge and its relation with fatigue: a multicenter prospective study. *Critical Care* 2014; **18**: 542.
3. Lasocki S, Lefebvre T, Mayeur C, et al. Iron deficiency diagnosed using hepcidin on critical care discharge is an independent risk factor for death and poor quality of life at one year: an observational prospective study on 1161 patients. *Critical Care* 2018; **22**: 314.
4. Docherty AB, Turgeon AF, Walsh TS. Best practice in critical care: anaemia in acute and critical illness. *Transfusion Medicine* 2018; **28**: 181–9.
5. Walsh TS, Saleh EE, Lee RJ, McClelland DB. The prevalence and characteristics of anaemia at discharge home after intensive care. *Intensive Care Medicine* 2006; **32**: 1206–13.
6. Warner MA, Hanson AC, Frank RD, et al. Prevalence of and recovery from anemia following hospitalization for critical illness among adults. *Journal of the American Medical Association Network Open* 2020; **3**: e2017843.
7. Warner MA, Kor DJ, Frank RD, et al. Anemia in critically ill patients with acute respiratory distress syndrome and posthospitalization physical outcomes. *Journal of Intensive Care Medicine* 2020. Epub 24 March. <https://doi.org/10.1177/0885066620913262>.
8. Shah A, Marian I, Dutton SJ, et al. Intravenous Iron to Treat Anaemia following CriTical care (INTACT): A protocol for a feasibility randomised controlled trial. *Journal of the Intensive Care Society*. 2019. Epub 5 September. <https://doi.org/10.1177/1751143719870080>.


doi:10.1111/anae.15461

Required software to e-Annotate PDFs: **Adobe Acrobat Professional** or **Adobe Reader** (version 11 or above). (Note that this document uses screenshots from **Adobe Reader DC**.)

The latest version of Acrobat Reader can be downloaded for free at: <http://get.adobe.com/reader/>

Once you have Acrobat Reader open on your computer, click on the **Comment** tab (right-hand panel or under the Tools menu).

This will open up a ribbon panel at the top of the document. Using a tool will place a comment in the right-hand panel. The tools you will use for annotating your proof are shown below:





1. Replace (Ins) Tool – for replacing text.



Strikes a line through text and opens up a text box where replacement text can be entered.

How to use it:

- Highlight a word or sentence.
- Click on .
- Type the replacement text into the blue box that appears.




2. Strikethrough (Del) Tool – for deleting text.



Strikes a red line through text that is to be deleted.

How to use it:

- Highlight a word or sentence.
- Click on .
- The text will be struck out in red.

experimental data if available. For ORFs to be had to meet all of the following criteria:



1. Small size (35-250 amino acids).
2. Absence of similarity to known proteins.
3. Absence of functional data which could not be the real overlapping gene.
4. Greater than 25% overlap at the N-terminus terminus with another coding feature; over both ends; or ORF containing a tRNA.


3. Commenting Tool – for highlighting a section to be changed to bold or italic or for general comments.



Use these 2 tools to highlight the text where a comment is then made.

How to use it:

- Click on .
- Click and drag over the text you need to highlight for the comment you will add.
- Click on .
- Click close to the text you just highlighted.
- Type any instructions regarding the text to be altered into the box that appears.





4. Insert Tool – for inserting missing text at specific points in the text.



Marks an insertion point in the text and opens up a text box where comments can be entered.

How to use it:

- Click on .
- Click at the point in the proof where the comment should be inserted.
- Type the comment into the box that appears.



5. Attach File Tool – for inserting large amounts of text or replacement figures.



Inserts an icon linking to the attached file in the appropriate place in the text.

How to use it:

- Click on .
- Click on the proof to where you'd like the attached file to be linked.
- Select the file to be attached from your computer or network.
- Select the colour and type of icon that will appear in the proof. Click OK.

The attachment appears in the right-hand panel.

chondrial preparator
ative damage injury
the extent of membra
malondialdehyde (TBARS) formation.
used by high perform

6. Add stamp Tool – for approving a proof if no corrections are required.



Inserts a selected stamp onto an appropriate place in the proof.

How to use it:


- Click on .
- Select the stamp you want to use. (The [Approved](#) stamp is usually available directly in the menu that appears. Others are shown under *Dynamic*, *Sign Here*, *Standard Business*).
- Fill in any details and then click on the proof where you'd like the stamp to appear. (Where a proof is to be approved as it is, this would normally be on the first page).

of the business cycle, starting with the
on perfect competition, constant ret
production. In this environment goods
extra costs are incurred to make marks
he total cost of production is deter
etermined by the model. The New-Key
otaki (1987), has introduced produc
general equilibrium models with nomin
and supply shocks. Most of this litera

APPROVED



Drawing tools available on comment ribbon




7. Drawing Markups Tools – for drawing shapes, lines, and freeform annotations on proofs and commenting on these marks.

Allows shapes, lines, and freeform annotations to be drawn on proofs and for comments to be made on these marks.

How to use it:

- Click on one of the shapes in the [Drawing Markups](#) section.
- Click on the proof at the relevant point and draw the selected shape with the cursor.
- To add a comment to the drawn shape, right-click on shape and select *Open Pop-up Note*.
- Type any text in the red box that appears.



For further information on how to annotate proofs, click on the [Help](#) menu to reveal a list of further options:

